Humana, Novo Nordisk partner for diabetes care
Humana Inc. and Novo Nordisk have announced a 1-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes.
Humana Inc. and Novo Nordisk have announced a 1-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes. The companies say they will bring together researchers to study the treatment and progression of the disease in an effort to further enhance the health and well-being of people with diabetes.
Nearly 26 million Americans have diabetes, according to the Centers for Disease Control and Prevention, and 7 million remain undiagnosed. Another 79 million Americans have pre-diabetes. The companies project that more Americans will develop diabetes as the population increasingly ages and grows more sedentary and overweight.
"This research collaboration is an important step in the fight against a disease that affects one out of every four Medicare members at Humana," said William Fleming, PharmD, President of Humana Pharmacy Solutions. "We are excited about working together with Novo Nordisk as we will meaningfully advance care and improve the lives of our members."
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
